Loading
A phase 3 trial testing F182112 in multiple myeloma, now recruiting.
A Multicenter, Randomised, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07579234, led by Shandong New Time Pharmaceutical, and recruiting on the registry. Official title: Phase III Clinical Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma. Planned enrolment is 261 participants (estimated). The study started in 2026-01-25 and primary completion is expected in 2029-01-25. No results have been posted on ClinicalTrials.gov.
Shares F182112, Shandong New Time Pharmaceutical, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.